Madison Vaccines Inc.
Vaccines for prostate cancer
This article was originally published in Start Up
Madison Vaccines Inc. is developing two candidates for prostate cancer: MVI-816 trains the patient’s immune system to recognize and attack the cancer as a foreign body by targeting a molecule called prostatic acid phosphatase (PAP), which is uniquely displayed on the surface of prostate cancer cells. Madison Vaccines’ second product, MVI-118, targets cells that over-express the androgen receptor.